The acquisition of Amylin Pharmaceutical’s (AMLN +0.1%) by AstraZeneca (AZN +0.1%) and...
The acquisition of Amylin Pharmaceutical’s (AMLN +0.1%) by AstraZeneca (AZN +0.1%) and Bristol-Myers Squibb (BMY -1.8%) this weekend has only whetted AZN's appetite for more purchases, says interim CEO Simon Lowth. The chief executive says the joint purchase reduces the drug giant's capital costs, and creates more flexibility for pipeline development and searching out new products, noting it has the cash and resources to make more acquisitions.
From other sites
Bristol Myers Squibb : OPINION: From the Editor: Fill Your Bucket List Foundation grants wishes to adult cancer patientsat 4-traders.com (Mar 24, 2015)
at Benzinga.com (Feb 26, 2015)
at Benzinga.com (Feb 25, 2015)
at CNBC.com (Feb 17, 2015)
at Investor's Business Daily (Jan 27, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs